293 related articles for article (PubMed ID: 11669297)
1. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
2. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
3. Improving Treatment for Myelodysplastic Syndromes Patients.
Montoro J; Yerlikaya A; Ali A; Raza A
Curr Treat Options Oncol; 2018 Oct; 19(12):66. PubMed ID: 30362079
[TBL] [Abstract][Full Text] [Related]
4. DNA-hypomethylating agents as epigenetic therapy before and after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Flotho C; Sommer S; Lübbert M
Semin Cancer Biol; 2018 Aug; 51():68-79. PubMed ID: 29129488
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: therapy and outlook.
Lyons RM
Am J Med; 2012 Jul; 125(7 Suppl):S18-23. PubMed ID: 22735747
[TBL] [Abstract][Full Text] [Related]
6. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?
Steensma DP
Best Pract Res Clin Haematol; 2012 Dec; 25(4):443-51. PubMed ID: 23200541
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
9. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
10. Update on the pharmacotherapy for myelodysplastic syndromes.
Duong VH; Komrokji RS; List AF
Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
[TBL] [Abstract][Full Text] [Related]
11. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
12. Strategies for achieving transfusion independence in myelodysplastic syndromes.
Thomas ML
Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
Stone R; Sekeres M; Garcia-Manero G; Lyons RM
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
[TBL] [Abstract][Full Text] [Related]
14. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
Gergis U; Wissa U
Curr Hematol Malig Rep; 2010 Jan; 5(1):1-8. PubMed ID: 20425390
[TBL] [Abstract][Full Text] [Related]
15. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
17. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
18. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of MDS].
Usuki K
Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
[No Abstract] [Full Text] [Related]
20. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
